E-Learning Ep. 2: ITI in the era of emicizumab episode artwork

EPISODE · May 8, 2023 · 17 MIN

E-Learning Ep. 2: ITI in the era of emicizumab

from EAHAD · host EAHAD - European Association for Haemophilia and Allied Disorders

Welcome to the second module of the EAHAD E-Learning Working Group podcast, where we are excited to feature Carmen Escuriola-Ettingshausen as our guest speaker. In this episode, Carmen will be discussing the topic of "ITI in the era of emicizumab". Emicizumab, a new therapeutic option for people with hemophilia A, has introduced new challenges for clinicians and patients, particularly in the realm of immune tolerance induction therapy. Carmen will delve into the impact of emicizumab on ITI therapy and provide practical insights into managing patients undergoing this treatment. So, sit back, relax, and join us in this insightful conversation with Carmen Escuriola-Ettingshausen. Do not forget to watch the full webinar on EAHAD Academy: https://academy.eahad.org/eahad/2023/module-2-iti-in-the-era-of-emicizumab/376716

Episode metadata supplied by the publisher feed · Published May 8, 2023

Embed this episode

Ready to play

E-Learning Ep. 2: ITI in the era of emicizumab

0:00 17:13

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of EAHAD?

This episode is 17 minutes long.

When was this EAHAD episode published?

This episode was published on May 8, 2023.

Can I download this EAHAD episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!